Haleon plc (HLN)vsIm Cannabis Corp (IMCC)
HLN
Haleon plc
$9.36
+1.63%
HEALTHCARE · Cap: $40.48B
IMCC
Im Cannabis Corp
$4.23
+143.10%
HEALTHCARE · Cap: $984,390
Smart Verdict
WallStSmart Research — data-driven comparison
Haleon plc generates 24248% more annual revenue ($11.15B vs $45.80M). HLN leads profitability with a 14.5% profit margin vs -39.1%. HLN earns a higher WallStSmart Score of 51/100 (C-).
HLN
Buy51
out of 100
Grade: C-
IMCC
Avoid31
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Strong operational efficiency at 23.9%
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
2.2% revenue growth
Grey zone — moderate risk
Earnings declined 4.5%
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -119.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : HLN
The strongest argument for HLN centers on Price/Book, Operating Margin.
Bull Case : IMCC
The strongest argument for IMCC centers on Debt/Equity.
Bear Case : HLN
The primary concerns for HLN are PEG Ratio, Revenue Growth, Altman Z-Score.
Bear Case : IMCC
The primary concerns for IMCC are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
HLN profiles as a value stock while IMCC is a turnaround play — different risk/reward profiles.
IMCC carries more volatility with a beta of 2.10 — expect wider price swings.
HLN is growing revenue faster at 2.2% — sustainability is the question.
HLN generates stronger free cash flow (792M), providing more financial flexibility.
Bottom Line
HLN scores higher overall (51/100 vs 31/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Haleon plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Haleon plc (HLN) is a leading global consumer health company, emerging as a spin-off from GlaxoSmithKline, dedicated to providing innovative health solutions through a robust portfolio of trusted brands, including Sensodyne, Panadol, and Voltaren. Focused on key segments such as oral care, pain relief, and dietary supplements, Haleon addresses evolving consumer needs while leveraging strong brand equity for sustained market presence. The company's commitment to sustainability and ongoing innovation, alongside strategic investments in product development, positions Haleon favorably for long-term growth and enhanced health outcomes, ultimately maximizing value for shareholders.
Visit Website →Im Cannabis Corp
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
IM Cannabis Corp. The company is headquartered in Tel Aviv-Yafo, Israel.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?